Corbus commencing one-year open-label extension to Resunab phase 2 study
Corbus Pharmaceuticals announced that it is commencing a one-year, open-label extension study of the ongoing Phase 2 clinical study of Resunab, JBT-101, for the treatment of skin-predominant dermatomyositis. This open-label extension was submitted to and reviewed by the U.S. FDA. The goal of the open-label extension dermatomyositis study is to provide all enrolled subjects with the option of receiving JBT-101 for one year after they complete the four-month, double-blind placebo controlled portion of the study and to collect long-term safety and efficacy on JBT-101. The safety and efficacy endpoints used in the double-blinded, placebo-controlled portion of the study will be assessed throughout the one year extension study. The Phase 2 study in skin-predominant dermatomyositis is funded by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health to the University of Pennsylvania School of Medicine.